Tarsier Pharma, a clinical-stage Israeli biotech developing steroid-free therapies for ocular diseases, filed an F-1 in April 2026 and updated terms in July for a $45-50 million NYSE American IPO at $8-10 per share, implying a roughly $294-299 million post-offer market cap. As of late August 2026, however, the offering remains unpriced with no effective registration or listing date, amid a cooling biotech IPO window and typical delays for Phase 3 assets lacking near-term catalysts. This underpins the 98.7% market-implied odds of no closing market cap before September 2026. A rapid pricing in the final days of August could still shift outcomes toward the $250-400 million buckets, though sustained quiet-period extensions or market volatility would reinforce the current consensus.
Résumé expérimental généré par IA à partir des données Polymarket. Ceci n'est pas un conseil de trading et ne joue aucun rôle dans la résolution de ce marché. · Mis à jourPas d’introduction en bourse avant septembre 2026 98.6%
350 M$-400 M$ <1%
<250 M$ <1%
250 M$-300 M$ <1%
$16,573 Vol.
$16,573 Vol.
31 août 2026
<250 M$
<1%
250 M$-300 M$
<1%
300 M$-350 M$
<1%
350 M$-400 M$
<1%
400 M$-450 M$
<1%
>450 M$
<1%
Pas d’introduction en bourse avant septembre 2026
99%
Pas d’introduction en bourse avant septembre 2026 98.6%
350 M$-400 M$ <1%
<250 M$ <1%
250 M$-300 M$ <1%
$16,573 Vol.
$16,573 Vol.
31 août 2026
<250 M$
$1,099 Vol.
<1%
250 M$-300 M$
$1,079 Vol.
<1%
300 M$-350 M$
$866 Vol.
<1%
350 M$-400 M$
$761 Vol.
<1%
400 M$-450 M$
$594 Vol.
<1%
>450 M$
$680 Vol.
<1%
Pas d’introduction en bourse avant septembre 2026
$11,495 Vol.
99%
This market will resolve based on Tarsier Pharma's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on July 9 (ET). If no such IPO occurs by August 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before September 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Tarsier Pharma, a clinical-stage Israeli biotech developing steroid-free therapies for ocular diseases, filed an F-1 in April 2026 and updated terms in July for a $45-50 million NYSE American IPO at $8-10 per share, implying a roughly $294-299 million post-offer market cap. As of late August 2026, however, the offering remains unpriced with no effective registration or listing date, amid a cooling biotech IPO window and typical delays for Phase 3 assets lacking near-term catalysts. This underpins the 98.7% market-implied odds of no closing market cap before September 2026. A rapid pricing in the final days of August could still shift outcomes toward the $250-400 million buckets, though sustained quiet-period extensions or market volatility would reinforce the current consensus.
This market will resolve based on Tarsier Pharma's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on July 9 (ET). If no such IPO occurs by August 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before September 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on July 9 (ET). If no such IPO occurs by August 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before September 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
Marché ouvert : Jul 7, 2026, 9:12 AM ET
Volume
$16,573Date de fin
1 sept. 2026Marché ouvert
Jul 7, 2026, 9:12 AM ETResolver
0x69c47De9D...This market will resolve based on Tarsier Pharma's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on July 9 (ET). If no such IPO occurs by August 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before September 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Tarsier Pharma, a clinical-stage Israeli biotech developing steroid-free therapies for ocular diseases, filed an F-1 in April 2026 and updated terms in July for a $45-50 million NYSE American IPO at $8-10 per share, implying a roughly $294-299 million post-offer market cap. As of late August 2026, however, the offering remains unpriced with no effective registration or listing date, amid a cooling biotech IPO window and typical delays for Phase 3 assets lacking near-term catalysts. This underpins the 98.7% market-implied odds of no closing market cap before September 2026. A rapid pricing in the final days of August could still shift outcomes toward the $250-400 million buckets, though sustained quiet-period extensions or market volatility would reinforce the current consensus.
This market will resolve based on Tarsier Pharma's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on July 9 (ET). If no such IPO occurs by August 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before September 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on July 9 (ET). If no such IPO occurs by August 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before September 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
Volume
$16,573Date de fin
1 sept. 2026Marché ouvert
Jul 7, 2026, 9:12 AM ETResolver
0x69c47De9D...Tarsier Pharma, a clinical-stage Israeli biotech developing steroid-free therapies for ocular diseases, filed an F-1 in April 2026 and updated terms in July for a $45-50 million NYSE American IPO at $8-10 per share, implying a roughly $294-299 million post-offer market cap. As of late August 2026, however, the offering remains unpriced with no effective registration or listing date, amid a cooling biotech IPO window and typical delays for Phase 3 assets lacking near-term catalysts. This underpins the 98.7% market-implied odds of no closing market cap before September 2026. A rapid pricing in the final days of August could still shift outcomes toward the $250-400 million buckets, though sustained quiet-period extensions or market volatility would reinforce the current consensus.
Résumé expérimental généré par IA à partir des données Polymarket. Ceci n'est pas un conseil de trading et ne joue aucun rôle dans la résolution de ce marché. · Mis à jourConnexes
CopperTech Metals ne fera-t-elle pas son entrée en bourse avant septembre 2026 ?
97%
Oui
La capitalisation boursière de Discord sera-t-elle comprise entre 8 et 11 milliards de dollars à la clôture du marché le jour de son introduction en bourse d'ici le 31 décembre 2027 ?
25%
Oui
Databricks n'aura-t-elle pas fait son entrée en bourse d'ici le 31 décembre 2027 ?
65%
Oui
Méfiez-vous des liens externes.
Méfiez-vous des liens externes.
Questions fréquentes